Rosetta Genomics Ltd. is an Israel-based company engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA), and protein biomarkers, and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). The Company is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY, and RosettaGX Reveal. The Company's therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. The Company focuses on developing a diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Closed - OTC Markets Other stock markets 02:31:08 2026-05-11 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-

18-05-30	Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd..	CI
18-05-21	Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index	CI

Market Cap	3.29M 2.84M 2.61M 2.45M 4.6M 311M 4.65M 30.86M 12.02M 152M 12.35M 12.09M 528M	P/E Ratio 2015	-1.07x	P/E Ratio 2016	-0.54x
Enterprise Value	845K 728K 671K 630K 1.18M 79.9M 1.19M 7.92M 3.09M 39.13M 3.17M 3.1M 136M	EV / Sales 2015	1.07x	EV / Sales 2016	0.73x
Free-Float	100%	Yield 2015 *	-	Yield 2016	-

18-05-30	Genoptix, Inc. cancelled the acquisition of Rosetta Genomics Ltd..	CI
18-05-21	Rosetta Genomics Ltd.(NasdaqCM:ROSG) dropped from NASDAQ Composite Index	CI
18-04-10	Rosetta Genomics Ltd. Announces Resignation of Ken Berlin as President and CEO, Effective April 18, 2018	CI
18-03-13	Genoptix, Inc. and Rosetta Genomics Ltd. Enter into Agreement to Market and Distribute Rosetta Genomics' Testing Services Worldwide	CI
18-03-01	Genoptix, Inc. completed the acquisition of PDx Business of Rosetta Genomics Ltd..	CI
18-02-26	Genoptix, Inc. entered into a definitive agreement to acquire PDx Business of Rosetta Genomics Ltd. for $1 million.	CI
18-02-26	Genoptix, Inc. entered into a merger agreement to acquire Rosetta Genomics Ltd. for $8 million.	CI
18-02-21	Genoptix, Inc. cancelled the proposed acquisition of Rosetta Genomics Ltd..	CI
17-12-14	Genoptix, Inc. entered into a term sheet agreement to acquire Rosetta Genomics Ltd..	CI
17-11-14	Rosetta Genomics Ltd. Announces Resignation of David Sidransky as Director	CI
17-11-01	Certain Ordinary Shares of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.	CI
17-11-01	Certain Stock Options of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.	CI
17-11-01	Certain Warrants of Rosetta Genomics Ltd. are subject to a Lock-Up Agreement Ending on 2-NOV-2017.	CI

Current year	0		0
1 year	0		0
3 years	0		0
5 years	0		0.07
10 years	0		18.6

Rosetta Genomics Ltd. Stock

Stocks

ROSGQ

IL0011026494

Biotechnology & Medical Research

Valuation: Rosetta Genomics Ltd.

Chart: Rosetta Genomics Ltd.

Latest news : Rosetta Genomics Ltd.

Press Releases: Rosetta Genomics Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Rosetta Genomics Ltd.

Other Biotechnology & Medical Research

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ROSETTA GENOMICS LTD.	-99.00%	-.--%	-	-	5
LONZA GROUP AG	-0.12%	+1.04%	-13.08%	-12.43%	43.58B
REVOLUTION MEDICINES, INC.	-2.17%	+5.45%	+285.76%	+522.83%	34.03B
IQVIA HOLDINGS INC.	+0.44%	-2.46%	+14.20%	-17.35%	29.77B
BEONE MEDICINES AG	-1.60%	-2.54%	-2.12%	+31.28%	29.82B
CELLTRION, INC.	-0.29%	+9.47%	+13.95%	+21.93%	25.42B
ASCENDIS PHARMA A/S	+3.54%	+12.34%	-	-	13.87B
MEDPACE HOLDINGS, INC.	-1.26%	+0.81%	+54.77%	+109.24%	13.35B
EUROFINS SCIENTIFIC SE	-1.04%	-3.33%	+3.98%	+3.91%	12.85B
IONIS PHARMACEUTICALS, INC.	-1.18%	-0.61%	+105.37%	+75.32%	12.22B
Average	-10.27%	+1.83%	+57.85%	+91.84%	21.49B
Weighted average by Cap.	-0.54%	+2.02%	+59.38%	+102.72%

	2015	2016
Net sales	8.27M 7.13M 6.56M 6.16M 11.57M 782M 11.69M 77.53M 30.2M 383M 31.03M 30.37M 1.33B	9.23M 7.96M 7.33M 6.88M 12.92M 873M 13.05M 86.59M 33.73M 428M 34.65M 33.92M 1.48B
Net income	-17.34M -14.95M -13.76M -12.92M -24.26M -1.64B -24.52M -163M -63.36M -803M -65.09M -63.71M -2.78B	-16.23M -13.99M -12.88M -12.1M -22.71M -1.53B -22.95M -152M -59.3M -752M -60.92M -59.63M -2.6B
Net Debt	-13.54M -11.67M -10.75M -10.09M -18.95M -1.28B -19.15M -127M -49.48M -627M -50.83M -49.75M -2.17B	-2.45M -2.11M -1.94M -1.82M -3.42M -231M -3.46M -22.94M -8.94M -113M -9.18M -8.98M -392M